Silo Pharma commends US federal push to fast-track psychedelic PTSD therapies

PUBT·04/29/2026 13:10:33

Listen to the news

Silo Pharma commended coordinated U.S. federal actions to fast-track psychedelic-based therapies for PTSD, citing an executive initiative to accelerate development.
CEO Eric Weisblum said federal funding, clinical progress, and regulatory prioritization are laying groundwork for new PTSD treatments.
Silo highlighted ARPA-H initial EVIDENT program awards as support for data-driven psychedelic research.
Company pointed to FDA IND clearance for DemeRx NB noribogaine in alcohol use disorder as evidence of expanding clinical activity in mental health.
Silo noted FDA issuance of three Commissioner’s National Priority Vouchers, citing imminent final guidance for psychedelic drug development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604290908PRIMZONEFULLFEED9709079) on April 29, 2026, and is solely responsible for the information contained therein.

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Contact Number :+852 3852 8500

Monday 7:00 AM - Saturday 9:00 AM (HKT)

Service Email :service@webull.hk

Online Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)

Business Cooperation :marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English